Zenotech Laboratories

Zenotech Laboratories Equity Ratio

The Equity Ratio of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is 85.58 %. In the previous year, Equity Ratio was 86.58 % — a change of -1.16% (lower).

Equity Ratio

85.58 %

YoY

-1.16%

Last updated:

Equity Ratio of Zenotech Laboratories is 2026 85.58 % . Equity Ratio of Zenotech Laboratories was 2025 86.58 % . It decreases by -1.16% lower compared to the previous year.

The Zenotech Laboratories Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
45.99 INR
Jan 1, 2020
58.01 INR
Jan 1, 2021
56.39 INR
Jan 1, 2022
75.08 INR
Jan 1, 2023
81.56 INR
Jan 1, 2024
85.25 INR
Jan 1, 2025
86.58 INR
Jan 1, 2026
85.58 INR
The Zenotech Laboratories Equity Ratio history
YEAREquity RatioYoY
85.58 %-1.16%
86.58 %+1.56%
85.25 %+4.53%
81.56 %+8.62%
75.08 %+33.15%
56.39 %-2.79%
58.01 %+26.14%
45.99 %-10.53%
51.40 %-139.58%
-129.87 %+49.19%
-87.05 %+106.22%
-42.21 %+332.88%
-9.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Equity Ratio of Zenotech Laboratories is 85.58 % in 2026.

Equity Ratio of Zenotech Laboratories changed from 86.58 % to 85.58 %, representing a -1.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories